BioPharmSignal logoBioPharmSignal

Company Profile

Crinetics Pharmaceuticals Stock Price, News & Catalysts

Ticker:
CRNX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

84.95 USD (+0.13%)

Close

Last updated: August 31, 2026

3.44B USD

Market cap

Why the stock is moving

Current closing-price context is not available for CRNX.

Company overview

Endocrine-Focused Pharmaceuticals

Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors.

PALSONIFY

PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It is designed to provide an oral alternative to injected peptide treatments.

Congenital Adrenal Hyperplasia

Crinetics is also developing therapies for congenital adrenal hyperplasia, including a pediatric program being evaluated in the Phase 2/3 BALANCE-CAH study.

Future catalysts

    Recent news

    1. 01

      Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

    2. 02

      Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

    3. 03

      Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

    4. 04

      Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFYâ„¢ (paltusotine) Provides Durable, Consistent Acromegaly Control

    5. 05

      Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    ACAD

    ACADIA Pharmaceuticals Inc.

    ALXN

    ALXN

    ANIP

    ANI Pharmaceuticals

    AVRO

    AVROBIO

    ABEO

    Abeona Therapeutics

    AGLE

    Aeglea Biotherapeutics

    AGIO

    Agios Pharmaceuticals, Inc.

    ALNY

    Alnylam Pharmaceuticals, Inc.

    Frequently Asked Questions

    What is the current stock price of Crinetics Pharmaceuticals (CRNX)?

    Crinetics Pharmaceuticals (CRNX) most recently closed at 84.95 USD, a +0.13% move versus the previous session.

    What is the market cap of Crinetics Pharmaceuticals (CRNX)?

    Crinetics Pharmaceuticals currently has a market capitalization of 3.44B USD on BioPharmSignal.

    What does Crinetics Pharmaceuticals do?

    Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors. PALSONIFY PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It...

    On which exchange is CRNX stock listed?

    Crinetics Pharmaceuticals (CRNX) is associated with NASDAQ, United States, Biopharma.

    What is BALANCE-CAH?

    Congenital Adrenal Hyperplasia Crinetics is also developing therapies for congenital adrenal hyperplasia, including a pediatric program being evaluated in the Phase 2/3 BALANCE-CAH study.

    Which conditions is Crinetics Pharmaceuticals targeting with BALANCE-CAH?

    Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors. PALSONIFY PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It...

    What is Endocrine-Focused?

    Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors.

    What is Pharmaceuticals?

    Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors.